Clinical Trial Planning and Design: What to Plan Before Execution

Effective clinical trial planning and design is needed to develop a study that can accurately, and without bias, answer a clearly defined research question. Rather than asking a broad question such as whether Treatment A works, a trial should aim to answer a more specific question, for example whether Treatment A improves a particular outcome compared with Treatment B in a defined population over a defined period.

This involves several interconnected concepts that need to be considered together if the trial is to be both scientifically credible and feasible to conduct. This article examines how the research question should guide study design, population, endpoints, treatment comparison, statistical planning, and feasibility.

In Brief

• Clinical trial planning and design turns a defined research question into a study structure that can generate interpretable evidence.
• Early design choices matter because population, endpoints, comparator, sample size and analysis are connected rather than independent decisions.
• Operationally, planning extends to recruitment, site capability, participant burden, resources and whether the resulting protocol can be delivered.
• A methodologically sound design can still fail in practice if recruitment assumptions, procedures or site requirements are unrealistic.
• The research question should remain the anchor for design, statistical and feasibility decisions throughout planning.

What does clinical trial planning and design need to achieve?

Properly supported planning and design should produce a clinical trial that can answer a prespecified, specific and clinically meaningful research question while remaining feasible to conduct.

During planning, it is important to consider whether the evidence collected will allow the study objective to be properly interpreted. This means defining the treatment effect that matters to the research question and using it as a basis for the design.

This treatment effect can later be formalised through an estimand as part of the statistical planning.

How does the research question shape clinical trial design?

The research question is the starting point for clinical trial design. Asking whether a new treatment is better than placebo, for example, creates a different trial from asking whether it is no worse than an established effective therapy.

A well-defined research question establishes who is being studied, what intervention is being evaluated, what it is being compared with, which outcome matters, over what period the effect should be assessed and under what circumstances that effect is of interest.

The treatment objective then translates this broader question into the specific treatment effect the study is intended to evaluate. The clinical question describes the problem the study is trying to answer, whereas the treatment objective describes more precisely what effect should be estimated. This helps determine the endpoint, comparator and analysis strategy.

Seemingly small differences in the question can materially alter the design. Asking whether treatment reduces symptoms at 12 weeks differs from asking whether it maintains symptom control over one year, even with the same treatment and population. These questions may require different endpoints, visit schedules, follow-up periods and analyses.

The research question should therefore guide the design rather than being constructed to fit an attractive or convenient study design.

How do you choose the right clinical trial study design?

The appropriate study design follows from the research objective and intended claim.

The intended claim is particularly important in determining whether the study assesses superiority, non-inferiority or equivalence. A superiority trial aims to demonstrate that one treatment performs better than another. A non-inferiority trial aims to show that a treatment is not unacceptably worse than an established comparator, while an equivalence trial aims to show that differences between treatments fall within predefined limits. These designs have different statistical and methodological requirements. Non-inferiority and equivalence studies, for example, may require substantial sample sizes depending on the chosen margin, assumed treatment effect, variability and expected event rates.

The research question may also lead to different choices in treatment allocation, sequencing or the number of treatment groups. Alternative designs include crossover studies, in which participants receive multiple treatments in sequence; factorial designs, which evaluate more than one intervention; multi-arm or dose-ranging studies; and cluster-randomised trials, where groups or sites rather than individuals are randomised.

A parallel-group design is one of the most common approaches, with participants remaining on their assigned treatment. Crossover designs can be useful where treatment effects are reversible and carryover can be controlled. Factorial designs allow multiple interventions and potentially their interaction to be assessed. Adaptive designs permit prespecified modifications based on accumulating data, while Bayesian approaches can incorporate prior information into design and inference.

How should the trial population and eligibility criteria be defined?

The trial population should represent the patients who most directly fit the research question. It is useful to distinguish between the target population for whom the treatment is intended and the patients who can realistically be recruited. If a treatment is intended for adults with moderate-to-severe disease, for example, recruiting predominantly patients with mild disease may make recruitment easier but reduce the relevance of the results.

Eligibility criteria translate the target population into operational rules that can be applied at study sites. These may include diagnostic criteria, age ranges, disease severity, laboratory thresholds, prior treatment requirements, comorbidities and restrictions on concomitant medication.

The characteristics of the population also affect the applicability of the results. A study conducted mainly in older men, for example, may have limitations when applied to younger patients or women if treatment effects or risks differ between these groups.

Eligibility criteria also have operational consequences. Restrictive criteria can increase screen-failure rates, slow recruitment and reduce the number of suitable patients available at individual sites. Requirements for specialist assessments, laboratory testing, imaging, washout periods or additional screening can make recruitment more difficult and may require additional training.

Population definition is therefore both a scientific and operational decision. The trial must include patients who allow the research question to be answered while ensuring that the study remains recruitable and relevant to clinical practice.

How should endpoints be selected in clinical trial design?

Endpoint selection should follow directly from the clinical objective. The endpoint needs to reflect what the study is trying to demonstrate, whether that is symptom improvement, survival, delayed disease progression, prevention, improved quality of life or another clinically meaningful effect.

Endpoint choice should also correspond to the exact treatment effect of interest. Change from baseline at a particular timepoint, for example, answers a different question from time to first clinically meaningful improvement, even if both concern the same disease outcome.

A trial will generally have a clearly defined primary endpoint used to address its main objective, together with secondary endpoints that provide supportive evidence, investigate additional benefits or risks, or characterise different aspects of treatment. Secondary endpoints should be planned carefully rather than regarded as a way to rescue a trial in which the primary endpoint has failed.

Endpoints can be continuous, binary, ordinal, count, time-to-event or recurrent-event outcomes. Trials may also use patient-reported outcomes, biomarkers, surrogate endpoints or composite endpoints. Endpoint type affects the statistical methods required and often has important consequences for sample-size calculation.

Endpoints need to be defined precisely, including what is measured, how it is measured, who performs the assessment, when it is measured, what constitutes an event or response and how repeated measurements are handled. These decisions affect the visit schedule, duration of follow-up, sample size, data collection requirements, adjudication, blinding, site training and handling of missing data.

Regulatory considerations may also influence endpoint selection. Endpoints should be clinically meaningful, appropriately validated where necessary and suitable for the intended claim.

How do comparator choice, randomisation, and blinding affect trial design?

The comparator provides the reference against which the treatment effect is interpreted. Depending on the objective and setting, this may be placebo, active control, standard of care, another dose, background therapy or, in specialised circumstances, a historical or external control. Comparator choice depends on existing treatment options, ethical considerations and the intended claim.

Randomisation and blinding control different sources of bias. Randomisation supports comparability between treatment groups by reducing systematic differences and limiting confounding, while blinding reduces the risk that behaviour, clinical management or outcome assessment is influenced by knowledge of treatment assignment. Allocation concealment addresses a separate source of bias by preventing treatment assignments from being known before a participant is enrolled and allocated. Together, these methods can also help limit avoidable variation between treatment groups.

Randomisation may be simple, blocked or stratified. Allocation ratios may vary and participants may be assigned using unequal allocation ratios such as 2:1, where appropriate. Important prognostic factors may be used as stratification variables to maintain balance between groups. In cluster-randomised trials, groups or sites rather than individual participants are randomised.

Blinding may range from open-label to single- or double-blind approaches. In some studies, complete blinding is impractical. Surgical interventions, visibly different devices or treatments with distinctive administration requirements may make allocation obvious. In these situations, blinded endpoint assessment or independent outcome adjudication can still reduce assessment bias.

Comparator choice and blinding therefore need to be considered together. An active comparator given by infusion and an investigational oral treatment, for example, may require a double-dummy design if maintaining blinding is important. Where an open-label design is unavoidable, independent blinded outcome assessment may provide an alternative.

How do sample size and statistical planning fit into clinical trial design?

Sample size and statistical planning should be considered early rather than added after the rest of the protocol has been developed. Sample-size calculations help determine whether the proposed treatment effect, endpoint and population can realistically be studied with the available participants, sites, time and resources.

The required sample size depends on assumptions including the expected treatment effect, variability, event rate, significance level, statistical power, allocation ratio, expected dropout and, where applicable, a non-inferiority or equivalence margin. Multiplicity, clustering and other design features may also need to be incorporated.

The planned statistical analyses should be defined prospectively. These include the primary analysis, analysis population, covariate adjustment, handling of missing data, subgroup analyses, multiplicity procedures and sensitivity analyses.

The estimand links the clinical question to these analyses. At a high level, an estimand defines the treatment effect the trial is trying to estimate by specifying the population, treatment condition, outcome, and approach to intercurrent events. Events after randomisation can complicate interpretation of the treatment effect, including treatment discontinuation, rescue medication, treatment switching, death or prohibited medication. How these intercurrent events are handled should follow from the clinical question rather than being decided after the results are known.

Internal consistency is also important. A sample-size calculation based on a particular endpoint timing, event rate, population and treatment effect may no longer be valid if those elements change. Statistical assumptions should therefore be revisited when important design decisions are modified.

Simulation and sensitivity analyses can explore uncertainty around these assumptions. For example, statisticians may assess what happens to power if dropout is higher than expected, event rates are lower, or the recruited population differs from planning assumptions.

Interim evaluations may also assess futility, efficacy, safety or sample-size assumptions. These should be planned prospectively, with appropriate control of type I error and independent data monitoring where necessary.

How do you test whether a clinical trial design is feasible and executable?

Feasibility assessments determine whether the assumptions made during trial design can actually be achieved. They may use historical studies, epidemiological data, site questionnaires, recruitment databases and feedback from investigators, clinicians and patients.

Recruitment is a major part of feasibility assessment. Teams should consider the number of eligible patients, expected recruitment rates, screen-failure rates, competing studies, the recruitment period and expected retention and dropout. A requirement for a rare biomarker, for example, may make an otherwise common disease population extremely difficult to recruit.

Site capability also needs to be assessed, including staff experience, equipment, laboratory and imaging facilities, pharmacy requirements, storage, visit capacity and access to suitable patients.

Participant burden can also have a major effect on feasibility. The number and length of visits, invasive procedures, travel, questionnaires, fasting, washout periods, blood sampling and long-term follow-up can influence willingness to participate and remain in the study. Excessive burden can therefore affect recruitment, adherence, missing data and dropout.

Timelines and resources should also be considered, including study start-up, site activation, enrolment, follow-up, monitoring, data cleaning, analysis, budget and staffing.

Feasibility work may reveal that assumptions need to change. Eligibility may need to be widened, visits reduced, more sites or countries added, recruitment extended or endpoint timing reconsidered.

The study protocol ultimately formalises these scientific and operational decisions into executable instructions, including objectives, design, population, treatments, endpoints, assessments, statistical principles and operational procedures. The protocol must also align with applicable ethical, regulatory and good clinical practice expectations, including relevant principles from ICH E6(R3), E8, E9 and E9(R1).

Conclusion

Effective clinical trial planning depends on making connected design decisions early enough to identify and resolve scientific and practical weaknesses before study execution begins. Population, endpoints, comparator, design, sample size, analysis and operational delivery are not independent decisions; changing one can have consequences for several others.

Scientific validity and operational feasibility should therefore be considered together. Ultimately, the research question should remain the anchor for these decisions so that the resulting evidence can credibly answer the question the trial was designed to address.

Quanticate’s statistical consultancy team supports drug development companies with clinical trial planning and design, from defining research questions and treatment effects to study design, sample size, statistical strategy and feasibility. If you would like to discuss how we could support your clinical trial planning, request a consultation, and a member of our team will be in touch.